Table 1.

Patient’s demographics and disease characteristics

	Overall (N = 431)
Trial, n (%)
▪SAKK 16/96	88 (20.4)
▪SAKK 16/00	231 (53.6)
▪SAKK 16/01	43 (10.0)
▪SAKK 16/08	69 (16.0)
Therapy group, n (%)
▪Bimodal	202 (46.9)
▪Trimodal	229 (53.1)
Age (years)
▪median (min, max)	59.8 (28.0-76.0)
Age group, n (%)
▪≥70 years	38 (8.8)
▪<70 years	393 (91.2)
Sex, n (%)
▪Female	126 (29.2)
▪Male	305 (70.8)
Smoking status, n (%)
▪Current smokers	149 (34.6)
▪Former smokers	249 (57.8)
▪Never smokers	32 (7.4)
▪Missing data	1 (0.2)
Smoking burden (pack-years)a
▪median (min, max)	45 (3-182)
Histological subtype, n (%)
▪Adenocarcinoma	166 (38.5)
▪Squamous cell carcinoma	158 (36.7)
▪Large cell carcinoma	34 (7.9)
▪Poorly differentiated NSCLC	71 (16.5)
▪Not otherwise specified	2 (0.5)
ECOG performance status, n (%)
▪0	285 (66.1)
▪1	145 (33.6)
▪2	1 (0.2)
Weight lossb, n (%)
▪<5%	198 (45.9)
▪≥5%	72 (16.7)
▪Missing data	161 (37.4)
Nodal status (TNM seventh edition), n (%)
▪N0	32 (7.4)
▪N1	4 (0.9)
▪N2	347 (80.5)
▪N3	48 (11.1)
T-stage (TNM seventh edition), n (%)
▪T1	51 (11.8)
▪T2	170 (39.4)
▪T3	144 (33.4)
▪T4	66 (15.3)
UICC stage (TNM seventh edition), n (%)
▪IIIA	354 (82.1)
▪IIIB	77 (17.9)

ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small-cell lung cancer; SAKK, Swiss Group for Clinical Cancer Research; TNM, tumor–node–metastasis; UICC, International Union Against Cancer (Union Internationale Contre le Cancer).

^aData collected for 389 patients.

^bData collected only for patients from SAKK 16/00 and SAKK 16/01 trials.